Profiles

Keywords
Last Name
Institution
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Philip Bonomi and Michael Liptay.

 
Connection Strength
  
 
 
0.880
  
  1. Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.121
  2. Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.109
  3. Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.102
  4. Kim AW, Faber LP, Warren WH, Basu S, Wightman SC, Weber JA, Bonomi P, Liptay MJ. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.096
  5. Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH, Bonomi P, Liptay MJ. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.093
  6. Tarhoni I, Fhied CL, Pool M, Liptay MJ, Bonomi P, Seder CW, Borgia JA. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
    View in: PubMed
    Score: 0.043
  7. Ziel E, Hermann G, Sen N, Bonomi P, Liptay MJ, Fidler MJ, Batus M, Warren WH, Chmielewski G, Sher DJ. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.037
  8. Daly S, Kubasiak JC, Rinewalt D, Pithadia R, Basu S, Fhied C, Lobato GC, Seder CW, Hong E, Warren WH, Chmielewski G, Liptay MJ, Bonomi P, Borgia JA. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.034
  9. Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.030
  10. Garg S, Gielda BT, Turian JV, Liptay M, Warren WH, Bonomi P, Sher DJ. Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):287-93.
    View in: PubMed
    Score: 0.030
  11. Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi O, Mahon B, Coon JS, Warren WH, Faber LP, Hong E, Bonomi P, Liptay MJ, Borgia JA. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.028
  12. Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, Faber LP. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.027
  13. Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon JS, DeCresce D, Thimothy L, Walters KA, Fhied C, Chang C, Chen SH, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.026
  14. Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.026
  15. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.026
  16. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
    View in: PubMed
    Score: 0.025
  17. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.